SCHEMBL2648599

SCHEMBL2648599

CCCCCc1c(Cc2ccc(C)c(O)c2)nc(C(C)C)c(CO)c1-c1ccc(F)cc1

nearest known ligand 0.66

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GCGR P47871 20/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2648592 0.84 GCGR (0.67) GCGR
SCHEMBL2647764 0.84 GCGR (0.84) GCGR
SCHEMBL2648271 0.84 GCGR (0.70) GCGR
SCHEMBL2662020 0.82 GCGR (0.77) GCGR
SCHEMBL2650668 0.81 GCGR (0.79) GCGR
SCHEMBL2647181 0.81 GCGR (1.00) GCGR
SCHEMBL2647356 0.81 GCGR (0.74) GCGR
SCHEMBL2649904 0.80 GCGR (0.77) GCGR
SCHEMBL2647169 0.80 GCGR (1.00) GCGR
SCHEMBL2649480 0.80 GCGR (1.00) GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed